Wice Daily Version News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(Reuters) -Pfizer said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies after most patients dropped out of an earlier trial with high rates of side effects such as nausea and vomiting. Although Pfizer has a once-daily version of the weight-loss pill in the works, the decision still marks a blow to its ambition of entering a booming market that analysts expect to be worth $100 billion by the end of the decade. Pfizer said the drug cut weight by as much as 13% at 32 weeks in adults with obesity and without type 2 diabetes in a mid-stage trial. ....

New York , United States , Eli Lilly Mounjaro , Manas Mishra , Mikael Dolsten , Novo Nordisk Wegovy , Eli Lilly , Shinjini Ganguli , Novo Nordisk , Chief Scientific Officer Mikael Dolsten , Michael Erman , Nausea And Vomiting , Eli Lilly , Wice Daily Version , Side Effects ,